Introduction

Why it matters in modern poultry production
– Rapid multiplication of Eimeria can produce substantial intestinal injury within a short period.
– Subclinical coccidiosis may reduce feed efficiency, growth and flock uniformity without dramatic clinical signs.
– High oocyst contamination of litter increases exposure and repeated infection pressure.
– Effective control requires attention to parasite biology, farm management and appropriate anticoccidial programmes.

Etiology
Seven major Eimeria species are recognized in chickens. E. acervulina and E. maxima are frequently encountered, while E. tenella is particularly pathogenic and associated with severe caecal disease and haemorrhage (Yaqub et al., 2023). Species differ in preferred intestinal sites, lesion patterns and pathogenicity.

Transmission
The principal route is faecal–oral transmission. Birds ingest sporulated oocysts from contaminated litter, feed, water, equipment or the environment. Moisture, oxygen and suitable temperature favour sporulation, allowing infective oocysts to accumulate and maintain the infection cycle (Pal et al., 2023).
Life Cycle of EIMERIA

Ingestion of sporulated oocysts → release of sporozoites → epithelial invasion → multiplication → gamete formation → oocyst formation → faecal shedding → environmental sporulation.

Clinical Signs
Severity depends on Eimeria species, infective dose, bird age, immunity and environmental management. Signs include reduced feed intake, depression, ruffled feathers, drooping wings, enteritis, diarrhoea or dysentery, poor growth and increased mortality in severe cases (Pal et al., 2023).
– Reduced body-weight gain and flock uniformity
– Poor feed conversion and production performance
– Diarrhoea or blood-stained droppings in severe infections
– Dehydration, weakness and depression
– Mortality when tissue damage and blood loss are extensive
Species-specific sites

Post-Mortem Lesions
Post-mortem examination helps identify likely Eimeria species and estimate the distribution and severity of intestinal damage. Lesion patterns should be interpreted with clinical findings, litter condition, performance data and, where appropriate, laboratory diagnosis (Pal et al., 2023; Yaqub et al., 2023).

Key lesion patterns

Prevention and Control
Effective control integrates anticoccidial programmes with litter management, hygiene, stocking-density control, ventilation and sound flock management. Continuous or inappropriate use of a single anticoccidial can contribute to reduced efficacy and resistance selection; rotation, shuttle programmes, combinations and vaccination are among approaches used for longer-term control (Usman et al., 2011; Chapman, 2017; Noack et al., 2019).

Anticoccidial programmes
– Rotation changes the active ingredient or mode of action between production cycles.
– Shuttle programmes use different anticoccidial strategies during different feed phases.
– Combination programmes can broaden anticoccidial activity and may help address reduced sensitivity when appropriately designed (Chapman & Rathinam, 2022).
– Vaccination can provide controlled exposure to selected Eimeria strains and support protective immunity.

Ionophore vs Chemical

Combination programmes
Combining compatible anticoccidial activities can broaden control and reduce dependence on a single mode of action. Programme selection should consider disease pressure, previous anticoccidial history, susceptibility patterns, compatibility and label requirements (Chapman & Rathinam, 2022).

STALLEN’S DUAL APPROACH TO COCCIDIOSIS CONTROL
Stallen South Asia offers a dual approach to coccidiosis management with Manacox Plus, bringing together ionophore and chemical anticoccidial activity in one formulation. This approach is designed to support practical, structured coccidiosis-control programmes while reducing dependence on a single mode of action.

MANACOX PLUS
Manacox Plus is a dual-active anticoccidial formulation combining an ionophore and a chemical anticoccidial. It contains Monensin Sodium 8% + Nicarbazin 8% for practical coccidiosis prevention programmes in broilers.
Key Product Points

WHY A DUAL APPROACH
Using monensin sodium together with nicarbazin brings ionophore and chemical anticoccidial activity into one formulation. This can fit structured prevention programmes where the objective is effective control without unnecessary reliance on a single mode of action. Use should follow the approved label and veterinary guidance.
Practical use
– Use within a planned farm coccidiosis-control programme.
– Maintain good litter quality, ventilation, stocking density and drinker management.
– Review anticoccidial history and flock response when planning future programmes.
– Follow approved dose, withdrawal period and compatibility instructions.

References are available on request.

Indian Animal Health Industry
The veterinary healthcare sector in India is experiencing significant growth, with the market size estimated to be USD 1.25 billion in 2024, projected to reach USD 1.89 billion by 2029, indicating a robust CAGR of 8.63% during the forecast period. This growth is particularly notable in the poultry industry, which has emerged as one of the fastest-growing sectors among livestock species. The poultry sector has evolved into a key supplier of affordable protein sources, driving the development of value chains that cater to consumer demand.

Stallen South Asia: Leading by Change and Setting a Standard
In response to this market dynamic, Stallen South Asia Private Limited has emerged as a key player, offering indigenous solutions and expertise in animal health. By bridging the gap between global standards and local requirements, companies like Stallen are not only contributing to the growth of the poultry industry but also fostering a resilient and sustainable ecosystem for animal health management in the country.

Stallen stands out as a leading name in India’s animal health sector, offering a diverse range of products tailored for poultry and cattle across four distinct divisions. These divisions encompass feed additives, biosecurity solutions, formulations, and vaccines, showcasing Stallen’s comprehensive approach to animal health management.

Strategic Collaborations and Industry Partnerships – 25 Years in the Marking
The company’s journey traces back to its inception in 1997. Since inception, Stallen has constantly developed to stay in line with the industry standard – in 2010 Stallen entered a JV with FATRO from Bologna, Italy. This JV enabled Stallen to import and distribute a wide range of killed and live vaccines, further solidifying its position in the market.

Global Reach and Market Presence
Over the 25 years, Stallen has expanded its footprint and capacities. Today, Stallen’s export operations span more than 50 countries across 6 continents serving as a testament to our product quality and service.
In an attempt to completely self suffienct, Stallen has backward integrated and control the end-to-end supply chain. As a result, they currently operate 5 different manufacturing locations in addition to the 2 supply plants of FATRO:
1) Feed Additives Manufacturing Unit in Palghar, Maharashtra
2) Feed Additives Manufacturing Unit in Sajjanpada, Maharashtra
3) Feed Additives and Cattle Feed Premix Manufacturing Unit in Alexandria, Canada
4) Therapeutics/Formulations Manufacturing Unit in Nandore, Maharashtra
5) Halquinol API Manufacturing Unit in Vatva, Gujarat

Focus on Quality and Regulatory Compliance
All of Stallen’s plants are certified and regularly audited by ISO, GMP, and FDA, along with approvals from international regulatory bodies, attestesting to their adherence to rigorous standards in manufacturing and product safety.

1) Feed Additives and Premix Factories in Maharashtra
Stallen South Asia Pvt. Ltd., based in Nandore, Maharashtra, India, specializes in manufacturing a wide range of feed additives and supplements. Their product portfolio includes antibacterial solutions, treatments targeting mycoplasmal infections, deworming agents, performance enhancers, anthelmintics, mineral supplements, toxin-binding formulations, antidiarrheals, growth promoters, anticoccidials, water sanitation products, fly control solutions, and disinfectants. These products are meticulously crafted and made available in various convenient forms such as tablets, boluses, powders, oral liquid solutions.

1. Manufacturing Process: The factory has specialized equipment and facilities for the manufacturing process. This includes mixing and blending equipment for creating formulations, granulation machinery for solid products, liquid mixing and filling lines for liquids, and packaging lines for various forms of products.
2. Quality Assurance: Quality control measures are integral to the manufacturing process. Raw materials are tested for purity and quality before use. During production, in-process checks are conducted to ensure consistency and adherence to specifications. Finished products undergo rigorous quality testing for efficacy, safety, and compliance with regulatory standards.
3. Regulatory Compliance: The factory operates in compliance with regulatory requirements set by local and international regulatory bodies, with approvals from China, Iran, Australia and more. This includes adherence to Good Manufacturing Practices (GMP) and documentation of processes to ensure product quality and safety.

2) Formulation Unit in Palghar, Maharashtra, India.
It is a crucial facility for manufacturing pharmaceutical products that range between regular therapeutic drugs as well as beta-lactam formulations.
1. Facilities and Equipment: The formulation unit is equipped with state-of-the-art facilities and machinery required for the formulation and production of pharmaceutical products. This includes equipment for mixing, blending, granulation, drying, and packaging. The capacities are built for effervescent tablets, liquid form (oral and topical), oral powder, bolus and ointment.

2. Quality Control: Throughout the formulation process, rigorous quality control measures are implemented to ensure that the final product meets regulatory standards and specifications. This includes testing the raw materials, in-process samples, and the finished product for purity, potency, stability, and safety.

3. Regulatory Compliance: The formulation unit operates in compliance with regulatory requirements set by authorities such as the Food and Drug Administration (FDA) in India. This includes adherence to Good Manufacturing Practices (GMP), documentation of processes, and regular inspections to ensure quality and safety standards are maintained.

3) “Stallen Unveils Cutting-Edge API Facility for Halquinol Production!”
To maintain its commitment to quality, affordability, and timely delivery, Stallen has commenced the production of Halquinol, a non-antibiotic growth promoter classified under hydroxy-quinolines. This compound comprises 5-chloro-8-hydroxyquinoline, 5,7-Dichloro-8-hydroxyquinoline, and 7-Chloro-8-hydroxyquinoline, with the product Halquinol 98% manufactured in accordance with BP 80 (British Pharmacopeia 1980) specifications. Stallen offers Halquinol 98% as a chemical API for use in veterinary formulations and feed additives, alongside the commonly available 60% and 12% variants. With its adherence to BP specifications and increased monthly production capacity, Stallen is well-equipped to cater to global demand, holding valid registrations for Halquinol in over 15 countries.

Stallen’s strategic vision includes gradually introducing a range of APIs from its Vatva facility, aiming to reduce reliance on imported products from China in the animal health sector. The Vatva plant marks the fifth addition to Stallen’s manufacturing infrastructure, complementing its existing feed additive and veterinary formulation facilities in Palghar, Maharashtra, as well as a feed premix and additive manufacturing unit in Canada. This strategic expansion underscores Stallen’s commitment to self-sufficiency and quality assurance in delivering essential solutions for animal health and nutrition.